Know Cancer

or
forgot password

Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study


N/A
18 Years
80 Years
Open (Enrolling)
Both
Diagnosis of Melanoma

Thank you

Trial Information

Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study


Inclusion Criteria:



- Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a
BRAF inhibitor

- Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC)
including an arm with an oral Akt inhibitor

- Able and willing to provide informed consent

Exclusion Criteria:

- Factors which in the investigator's opinion would prevent the participant from
completing the protocol, including poor compliance during previous studies or an
unpredictable schedule

- Unable to give informed consent

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

Drop in systolic blood pressure before and after Akt treatment

Outcome Time Frame:

8 hours

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

120390

NCT ID:

NCT01593579

Start Date:

May 2012

Completion Date:

May 2016

Related Keywords:

  • Diagnosis of Melanoma
  • melanoma
  • autonomic failure
  • hypotension
  • akt therapy
  • Melanoma

Name

Location

Vanderbilt UniversityNashville, Tennessee  37232-6305